Short-Term Anticoagulation After Cardioversion in New-Onset Atrial Fibrillation and Low Thromboembolic Risk: A...

Area of Science:

• Cardiology
• Internal Medicine
• Clinical Practice Guidelines

Background:

• International guidelines present conflicting recommendations for short-term oral anticoagulation (OAC) after cardioversion in recent-onset atrial fibrillation (AF) for low-risk patients (CHA2DS2-VA = 0).
• Evidence supporting OAC in this specific scenario is limited, leading to varied clinical approaches across different regions.
• This study addresses the clinical dilemma of balancing ischemic and bleeding risks in the absence of strong evidence-based guidance.

Purpose of the Study:

• To assess international physician management practices for oral anticoagulation (OAC) in low-risk patients undergoing cardioversion for recent-onset atrial fibrillation (AF).
• To investigate how physicians balance the risks of stroke and bleeding in a clinical setting with ambiguous evidence-based recommendations.
• To evaluate adherence to existing guidelines regarding OAC administration post-cardioversion.

Main Methods:

• A review of six international AF guidelines was conducted to assess recommendations and evidence for short-term OAC post-cardioversion.
• An international questionnaire was developed using Google Forms and distributed to physicians across Italy, France, and Canada.
• Physicians from cardiology, internal medicine, ICU, geriatrics, and emergency medicine participated, with 78 responses collected.

Main Results:

• Younger physicians and cardiologists were more likely to prescribe OAC compared to older physicians or those in other specialties.
• Significant differences in periprocedural imaging (transoesophageal echocardiogram) and long-term rhythm control strategies (pulmonary vein isolation) were observed between European and Canadian centers.
• No statistically significant association was found between guideline adherence and OAC administration decisions.

Conclusions:

• Real-world antithrombotic management for low-risk, acutely cardioverted AF patients shows significant variation across healthcare systems.
• Cardiology departments may benefit from reducing the time threshold for safely withholding OAC, ensuring access to direct oral anticoagulants (DOACs), and considering regional stroke risk.
• Implementing strategies to prevent hemorrhage in patients receiving short-term OAC could mitigate cardioversion-related complications in this population.